Allianz Asset Management GmbH Acquires Shares of 8,100 Celcuity, Inc. $CELC

Allianz Asset Management GmbH acquired a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,100 shares of the company’s stock, valued at approximately $400,000.

Several other hedge funds also recently made changes to their positions in the company. Ogorek Anthony Joseph NY ADV purchased a new stake in Celcuity during the 3rd quarter valued at $27,000. BNP Paribas Financial Markets increased its holdings in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares during the period. Tower Research Capital LLC TRC raised its position in Celcuity by 211.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after purchasing an additional 3,766 shares during the last quarter. Avanza Fonder AB bought a new position in Celcuity during the 3rd quarter valued at approximately $79,000. Finally, Versant Capital Management Inc lifted its holdings in Celcuity by 611.2% in the 3rd quarter. Versant Capital Management Inc now owns 1,593 shares of the company’s stock worth $79,000 after buying an additional 1,369 shares during the period. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Price Performance

Shares of CELC opened at $104.51 on Friday. Celcuity, Inc. has a fifty-two week low of $7.57 and a fifty-two week high of $120.32. The firm’s 50-day simple moving average is $105.39 and its two-hundred day simple moving average is $78.30. The stock has a market cap of $4.84 billion, a PE ratio of -28.48 and a beta of 0.36. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26.

Celcuity (NASDAQ:CELC) last released its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.13. Analysts anticipate that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Insider Activity

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $105.69, for a total value of $317,070.00. Following the transaction, the director directly owned 6,760 shares of the company’s stock, valued at approximately $714,464.40. This trade represents a 30.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the transaction, the director directly owned 90,000 shares in the company, valued at approximately $10,802,700. The trade was a 18.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 26,900 shares of company stock worth $3,094,917 over the last three months. 15.77% of the stock is currently owned by insiders.

Analysts Set New Price Targets

CELC has been the topic of several research analyst reports. Stifel Nicolaus boosted their target price on Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Wolfe Research assumed coverage on shares of Celcuity in a research report on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price objective on the stock. Craig Hallum raised their target price on shares of Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Jefferies Financial Group lifted their target price on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Finally, HC Wainwright reiterated a “neutral” rating and set a $94.00 price target (up previously from $77.00) on shares of Celcuity in a research report on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Celcuity has an average rating of “Moderate Buy” and an average price target of $105.25.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.